In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...

CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and fat storage. Preclinical studies showed strong metabolic benefits, ...

Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) ...

A record-breaking 4,432 scientific abstracts accepted at the American Heart Association’s meeting here adorned posters, ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at ...

Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025--Phase 1 ...

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

From tumor profiling to CAR-T optimization, AI is accelerating discovery and decision-making in immuno-oncology. PICI researchers are leveraging multimodal data and large language models to predict ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

A Florida teacher claimed he was forced to remove a Charlie Kirk poster from his classroom after a student complained, a move that he says was political discrimination. William Loggans, who teaches ...